PDCD1 and non-small cell lung carcinoma: Nivolumab is a fully human IgG4 antibody targeting PD-1, administered intravenously, with a mean half-life time (t1/2) of 25 days and it was the first ICI approved by the U.S. FDA to treat advanced NSCLC patients [224].